Syndax Pharmaceuticals, Inc. (SNDX) Dividend History

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies. The company is known for its use of epigenetic modulators, particularly histone deacetylase (HDAC) inhibitors, to enhance the effectiveness of immunotherapies and targeted treatments. Syndax's lead investigational drug, Axzagertib (formerly Entinostat), aims to improve outcomes in various cancers by modulating the tumor microenvironment and overcoming resistance mechanisms.

35 Gatehouse Drive, Waltham, MA, 02451
Phone: 781-419-1400
Website: https://www.syndax.com

Dividend History

Syndax Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Syndax Announces Participation in June Investor Conferences

    Syndax Pharmaceuticals announced that it will present data on its cancer therapies Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) at the upcoming EHA 2025 conference.

    GlobeNewswire Inc.
  • Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates

    Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.

    Zacks Investment Research
    Featured Companies: INCY LLY
  • Analyst Ratings for Syndax Pharmaceuticals

    Within the last quarter, Syndax Pharmaceuticals (NASDAQ:SNDX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 5 3 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targets for Syndax Pharmaceuticals. The company has an average price target of $36.82 with a high of $42.00 and a low of $30.00. Below is a summary of how these 11 analysts rated Syndax Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, ...Full story available on Benzinga.com

    Benzinga
  • SmileDirectClub shares plunge after bankruptcy filing, with Syndax and AMC shares climbing and other active stocks

    Shares of SmileDirectClub, Syndax Pharmaceuticals, AMC and Chinese automakers were most active ahead of Monday's market open.

    MarketWatch
    Featured Companies: AMC
Page data last updated 07/23/2025 16:10:54 UTC